AMD - IVERIC bio GAAP EPS of -$0.47 misses by $0.10

• IVERIC bio press release ( NASDAQ: ISEE ): Q4 GAAP EPS of -$0.47 misses by $0.10 .
• As of December 31, 2022, the company had approximately $646.8M in cash, cash equivalents and available-for-sale securities.
• The company estimates that its cash, cash equivalents, available-for-sale securities and committed loan facilities will be sufficient to fund its planned capital expenditure requirements, debt service obligations and operating expenses for at least the next 12 months.
• CEO comment: “We are excited to begin 2023 with the FDA’s acceptance of the filing of our new drug application (NDA) and granting of priority review for ACP for the treatment of GA secondary to age-related macular degeneration ( AMD ). With the achievement of these important milestones, we move closer to our goal of providing patients with a treatment for GA, a devastating disease that leads to irreversible blindness.”

For further details see: